Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05731141 · ClinicalTrials.gov registry record
A Prospective Natural History Study of Lymphatic Anomalies
A clinical trial of Lymphatic Diseases and Lymphatic Abnormalities, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Recruiting
- Registry status
- 1,200
- Enrollment target
- 2
- Study locations
NCT05731141 is a study of Lymphatic Diseases and Lymphatic Abnormalities that is actively recruiting participants, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 1,200 participants, above the 64-participant average among 6 other Lymphatic Diseases trials with a reported enrollment target (1775% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT05731141, a study of Lymphatic Diseases and Lymphatic Abnormalities, is actively recruiting participants, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: The lymphatic system is a network of vessels that carry a clear fluid called lymph through the body. Problems in the lymphatic system can cause pain, fluid buildup, and issues with immunity. There is much researchers do not understand about lymphatic anomalies. In this natural history study, they will collect data from a lot of people over a long time. Objective: To better understand why lymphatic anomalies develop. The goal is to improve future treatments. Eligibility: People aged 0 days and older with a suspected or confirmed lymphatic anomaly. Their unaffected parents or siblings aged 7 years or older are also needed. Design: Participants may remain in the study indefinitely. Affected participants may be evaluated every 10 months to 2 years. Some participants will be seen over telemedicine. Others will be seen at the NIH Clinical Center for 2-5 days. All participants will have a physical exam. They may provide specimens including blood, saliva, hair follicles, stool, skin, and other tissues. Samples may be used for genetic testing. Participants may undergo other tests depending on their medical conditions. The NIH Clinical Center visit may include: Heart tests include placing stickers on the chest to measure electrical activity and using sound waves to capture pictures of the heart. A lung test measures the muscle strength in the chest. Participants will blow into a tube. Photographs may be taken of participants faces and other features. Imaging scans will take pictures of the inside of the body. One scan will measure bone density. One type of scan tracks how lymph fluid moves through the body. Participants will be under anesthesia, and they will be injected with a dye.
Conditions Studied
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2023-03-20 |
| Est. Completion | 2028-12-31 |
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)305 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05731141
The ClinicalTrials.gov registry entry for NCT05731141 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 64-participant average among 6 other Lymphatic Diseases trials with a reported enrollment target (1775% higher). The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphatic Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT05731141 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05731141 about?
NCT05731141 is a clinical study titled "A Prospective Natural History Study of Lymphatic Anomalies". Background: The lymphatic system is a network of vessels that carry a clear fluid called lymph through the body. Problems in the lymphatic system can cause pain, fluid buildup, and issues with immunity. There is much researchers do not understand about lymphatic anomalies. In this natural history s...
What is the current status of trial NCT05731141?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2023-03-20. Estimated completion is 2028-12-31.
What conditions does trial NCT05731141 study?
This clinical trial studies the following conditions: Lymphatic Diseases, Lymphatic Abnormalities.
Who is sponsoring clinical trial NCT05731141?
This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05731141 being conducted?
This trial has 2 study locations across Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphatic Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
RECRUITING · NA
-
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
ACTIVE NOT RECRUITING · Phase 1
-
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
ACTIVE NOT RECRUITING · Phase 1
-
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.